Prevalence of human papilloma virus (HPV) and its genotypes in cervical specimens of Egyptian women by linear array HPV genotyping test by unknown
RESEARCH ARTICLE Open Access
Prevalence of human papilloma virus (HPV)
and its genotypes in cervical specimens of
Egyptian women by linear array HPV
genotyping test
Mohamed A. Youssef1,10*, Lobna Abdelsalam2, Reem Abdelhameed Harfoush3, Iman Mamdouh Talaat4,
Eman Elkattan1, Abeer Mohey5, Rana M. A. Abdella1, Marwa Salah Farhan6, Hany Ahmed Foad5,
Abeer Mostafa Elsayed7, Naglaa A. Elkinaai7, Doaa Ghaith6, Mohamed Elsayed Rashed8, Mohamed Abd-El Ghafar9,
Yasser Khamis9 and Ahmed N. Hosni1
Abstract
Background: The association of human papillomavirus (HPV) with cervical cancer is well established.
Aim: To investigate HPV genotype distribution and co-infection occurrence in cervical specimens from a group of
Egyptian women.
Methods: A group of 152 women with and without cervical lesions were studied. All women had cervical cytology
and HPV testing. They were classified according to cytology into those with normal cytology, with squamous
intraepithelial lesions (SIL) and invasive squamous cell carcinoma (SCC). Cervical samples were analyzed to identify
the presence of HPV by PCR, and all positive HPV-DNA samples underwent viral genotype analysis by means of
LINEAR ARRAY HPV Genotyping assay.
Results: A total of 26 HPV types with a prevalence of 40.8 % were detected. This prevalence was distributed as
follows: 17.7 % among cytologically normal females, 56.5, 3.2, and 22.6 % among those with LSIL, HSIL and invasive
SCC respectively. Low-risk HPV types were detected in 81.8 % of the cytologically-normal women, in 5.7 % of those
in LSIL women, and in 14.3 % of infections with invasive SCC, while no low-risk types were detected in HSIL. High-risk
HPV types were detected in 18.2 % of infections in the cytologically normal women, 14.3 % of infections in LSIL, and
in 21.4 % of invasive lesions. The probable and possible carcinogenic HPV were not detected as single infections.
Mixed infection was present in 80 % of women with LSIL, in 100 % of those with HSIL, and in 64.3 % of those with
invasive SCC. This difference was statistically significant. HPV 16, 18 and 31 were the most prevalent HR HPV types,
constituting 41.9, 29.03 and 12.9 % respectively, and HPV 6, 62 and CP6108 were the most prevalent LR HPV types
constituting 11.3, 9.7 and 9.7 % respectively.
Conclusion: These data expand the knowledge concerning HPV prevalence and type distribution in Egypt which
may help to create a national HPV prevention program. HPV testing using the LINEAR ARRAY HPV Genotyping assay is
a useful tool when combined with cytology in the diagnosis of mixed and non-conventional HPV viral types.
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Background
With 528 000 new cases every year, cervical cancer is
the fourth most common cancer affecting women world-
wide [1]. Almost 70 % of the global burden falls in areas
with lower levels of development [2]. Persistent infection
with human papillomavirus (HPV) is the principal cause
of cervical cancer and its precursor cervical intraepithe-
lial neoplasia (CIN) [3].
Data is not yet available on the HPV burden in the gen-
eral population of Egypt. Current estimates indicate that
cervical cancer ranks as the 13th most frequent cancer
among women in Egypt and the 10th most frequent can-
cer among women between 15 and 44 years of age [4].
About 40 HPV types can infect the genital mucosa.
However, only a restricted group of HPVs, termed high-
risk (HR) HPVs, are associated with high-grade cervical
precancer lesions (CIN) or cervical cancer, while the low-
risk (LR) types are generally associated with condylomas
or other benign epithelial lesions [5].
HR-HPV 16 and 18 are estimated responsible for nearly
70 % of cervical cancer cases worldwide [6]. In Northern
Africa, the region Egypt belongs to, about 3.0 % of women
in the general population are estimated to harbor cervical
HPV-16/18 infection at a given time and 81.2 % of inva-
sive cervical cancers are attributed to HPVs 16 or 18 [4].
Development of cellular dysplastic changes is influenced
by numerous factors, such as smoking habit, immune sup-
pression, oral contraceptive use, hormone replacement
therapy as well as host genetic makeups [7–9]. Progres-
sion of the initial cytopathologic process to micro invasive
and invasive cancer usually takes decades [10].
Two types of prophylactic vaccines have been devel-
oped to prevent cervical cancer: a bivalent vaccine
against HR-HPV 16 and 18, and a tetravalent vaccine
against HR-HPV 16/18 and LR-HPV 6 and 11 [10–12].
Some studies suggest that these vaccines seem to pro-
tect against some HPV 16-related types (31, 33, 35 and
52) and HPV 18-related types (39, 45, 59, 68 and 85) [13].
Cervical cancer prevention programs in both develop-
ing and developed nations have generally relied on cyto-
logical testing using the conventional Papanicolaou’s
(Pap) test [14, 15]. However, cervical cytology suffers
from relatively high false-negative rates (low sensitivity)
as well as high false-positive rates (low specificity) [15].
The presence of HPV episomal DNA in the epithelial
cells is often associated with koilocytotic atypical changes
as the manifestation of HPV-induced cytopathology in
cervical dysplasia, a reversible early precancerous path-
ology which can be recognized on Pap smears and in his-
topathologic sections as low-grade cervical intraepithelial
neoplasia (CIN1), the precursor stage in the development
of a CIN2 and a CIN3 lesion [16]. This link between a vir-
ology finding and cytopathic changes in cervical carcino-
genesis has led to the proposed guidelines of using HPV
DNA testing to replace the traditional Pap smear cytology
as the primary screening for referral to colposcopy of
HPV-16/HPV-18-positive women with negative cytology
for cervical cancer prevention [17, 18].
The HPV DNA test used to replace the traditional Pap
cytology screening for precancerous cells and cancer
cells in the cervico-vaginal samples must be highly sensi-
tive, capable of detecting not only the HPV DNA with
high copy number in the koilocytes of the low grade
CIN lesions, but also the HPV DNA in the cervical can-
cers which may have as low as one single copy of HPV
DNA per cancer cell, and to generate a reliable genotyp-
ing result of the detected HPV. Most commercially avail-
able HPV test kits have been shown to be suboptimal in
analytical sensitivity and typing specificity [19].
This study main objective was to assess the prevalence
of HPV genotypes in Egyptian women, attending routine
gynecological examinations in different age groups, with
and without pre-invasive and invasive cervical lesions
and its correlation to findings in cytology. The study also
provides useful information on the performance and
clinical validity of HPV screening using the LINEAR
ARRAY HPV Genotyping test.
Methods
Study design and population
This multicenter, cross sectional study included 152 fe-
male subjects seeking routine gynecologic care at the fam-
ily planning and gynecological outpatient clinic, Al Kasr
Al Aini University Hospital, Cairo, and the outpatient
clinics of the Obstetrics and Gynecology Department at El
Shatby Maternity Hospital, Alexandria University, during
the period from January 2013 through May 2014. The in-
clusion criteria for patient selection included age 20 years
and over, chronic vaginal infection, post-coital bleeding,
irregular menstruation, and lower-back pains. The object-
ive of the study was explained and written consent was
obtained from each participant according to the ethics
committee guidelines.
Ethical considerations
The study was conducted in accordance with the Declar-
ation of Helsinki and the protocol of the study was ap-
proved by the Faculty of Medicine, Alexandria University
Ethics Committee prior to its start.
The participants were subjected to:
1. Complete history taking: Residency (rural or urban),
occupation, smoking, contraception, and
reproductive history (parity)
2. Cytology sample: Cervical cell scrapings were collected
by a gynecologist with a cytobrush from the ecto- and
endo-cervix of the uterus. A slide was prepared for
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conventional Pap cytology and the cytobrush was then
placed in specimen transport medium and transported
in PreservCyt Solution (Roche diagnostics, USA). Sam-
ples were stored at –80 °C until HPV molecular
analysis. Cytological findings were classified in line
with the 2004 Bethesda classification system [14], as
follows: (1) within normal limits or reactive cellular
changes (normal), (2) atypical squamous cells (a) low-
grade squamous intraepithelial lesion (LSIL), and (b)
high-grade squamous intraepithelial lesion (HSIL).
3. Colposcopy: for suspicious lesions.
4. Tissue biopsies were taken from suspicious lesions on
colposcopic examination. The histologic diagnosis of
the squamous lesions was classified according to the
WHO nomenclature and criteria as follows [16];
Cervical Intraepithelial Neoplasia (CIN) grade 1
(CIN 1), grade 2 (CIN 2), grade 3 (CIN 3), and
invasive SCC.
5. HPV detection
i. DNA extraction: from cervical samples using
(AmpliLute Liquid Media Extraction Kit),
according to the manufacturer’s instructions.
Extracted HPV and human genomic DNA
were immediately stored at−20° C until PCR
amplification.
ii. Screening PCR [20]: for the detection of HPV DNA
presence in the cervical samples, before
proceeding to genotyping, as follows:
– β-Globin gene PCR: DNA integrity was
assessed by PCR amplification of a 268 bp
segment of the human β-Globin gene using




– HPV PCR: β-Globin positive samples were
subjected to PCR that amplifies 450 bp prod-
uct for L1 open reading frame (ORF) of
HPV, using forward primer; 5′-TTTGTTA
CTGTGGTAGATACTAC-3′ and reverse
primer; 5′-AAAAATAAACTGTAAATCAT
ATTC-3′ as previously described. Each run
included an HPV positive control and a
negative (water) control. The amplification
products were visualized by means of elec-
trophoresis analysis on 2 % agarose gels con-
taining ethidium bromide (0.5 mg/ml).
iii. HPV genotyping:
HPV positive samples were genotyped using the
LINEAR ARRAY HPV Genotyping test (LA):
(Roche Diagnostics, Indianapolis, IN, USA).
This technique is based on PCR amplification of
target DNA using L1 consensus HPV primer
PGMY09/11, hybridization of the amplified
product to oligonucleotide probes and their
detection by colorimetric reaction. Particularly,
the master mix contains primers for the
amplification of a 450-bp fragment of the L1
region of more than 37 HPV genotypes and a
268-bp fragment of the human β- globin gene.
The detection and genotype determination was
performed using the denatured amplified DNA
and an array of oligonucleotide probes, located
in the polymorphic region of L1 that permitted
independent identification of individual HPV
genotypes. Negative samples were included in
each assay to demonstrate the specificity of the
test. The HPV types detected include 12 HR-
HPV genotypes (HPV16, 18,31, 33, 35, 39, 45,
51, 52, 56, 58, 59), 1 probably carcinogenic
(HPV 68), 13 LR-HPV genotypes (HPV6, 11, 40,
42, 54, 55, 61,62,72, 81,83, 84 and CP6108), 7
possibly carcinogenic genotypes (HPV 26, 66,
53, 67, 70, 73, 82) and 4 genotypes for which
the risk is still undetermined (HPV64, 69, 71,
and IS39)]
Statistical analysis
Data were fed to the computer and analyzed using IBM
SPSS software package version 20.0. Qualitative data
were described using frequency and percentage. Quanti-
tative data were described using range (minimum and
maximum), mean, and standard deviation. Comparison
between different groups regarding categorical variables
was tested using Chi-square test. When more than 20 %
of the cells have expected count less than 5, correction
for chi-square was conducted using Yate’s correction
(linear-by-linear association) for 2x2 tables or Monte
Carlo Correction for >2x2 tables. Comparison between
two independent populations was done using independ-
ent samples t-test. Significance of the obtained results
was judged at the 5 % level.
Results
One hundred fifty two female subjects seeking routine gy-
necologic care at the family planning and gynecological
outpatient clinic, Al Kasr Al Aini University Hospital,
Cairo, and the outpatient clinics of the Obstetrics and
Gynecology Department at El Shatby Maternity Hospital,
Alexandria University, were recruited. Table 1 shows the
demographic, clinical and laboratory characteristics of the
studied group. Regarding the cyto and histo-pathological
findings of the studied specimens, the cases were catego-
rized into normal (Fig. 1a), LSIL (Fig. 1b), HSIL (Fig. 1c)
and invasive SCC (Fig. 1d) in 67.1, 21.7, 2.0, and 9.2 % re-
spectively. The percentage of HPV positivity in the studied
specimens was 40.8 % (62/152).
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Table 2 investigates the relation between the risk factors
and HPV infection. It was shown that HPV positive cases
were mainly in age groups between 26–30 years and 31–35
years (30.6 %), and this distribution was statistically insig-
nificant (p = 0.741). The reproductive history, residence,
occupation, smoking habit, use of contraception and his-
tory of irregular genital bleeding of the studied group
showed a statistically insignificant difference between HPV
negative and positive cases. The only finding that showed
statistical significance in relation to HPV status was the
presence of genital warts (P = 0.000). Table 2 shows also
the distribution of HPV DNA status according to cervical
cytology and biopsy results. All HPV negative cases
showed normal cytology, while 82.3 % of the HPV positive
cases showed cytological changes: 56.5 % with LSIL, 3.2 %
with HSIL and 22.6 % with invasive SCC. The % raw re-
sults showed that 10.9 % of the normal cytology results
were HPV positive, while all abnormal cytology and biopsy
samples were HPV positive. This distribution was statisti-
cally significant (P = 0.000).
Table 3 demonstrates that 23 women were found to be
infected by a single HPV type (10 HR and 13 LR types)
while 39 women showed co-infection. The prevalence of
HPV-positive cases among normal Pap smears was 17.7 %
(11/62), whereas the prevalence among those with LSIL,
HSIL and invasive SCC was 56.5 % (35/62), 3.2 % (2/62),
and 22.6 % (14/62), respectively. LR HPV types were de-
tected in 81.8 % (9/11) of the infections in cytologically
normal women, in 5.7 % (2/35) in women presenting with
LSIL and in 14.3 % (2/14) of infections diagnosed with in-
vasive SCC, while no LR types were detected in HSIL. HR
HPV types were detected in 18.2 % (2/11) of infections in
cytologically normal women, in 14.3 % (5/35) of infections
in LSIL, and in 21.4 % (3/14) invasive lesions. The prob-
able and possible carcinogenic HPV were not detected as
single infections. HPV DNA was detected as mixed infec-
tion in 80 % (28/35) of women with LSIL, in 100 % (2/2)
of those with HSIL, and in 64.3 % (9/14) of those with in-
vasive SCC. The difference in the distribution was statisti-
cally significant (p = 0.000).
Table 4 shows that a total of 26 different HPV types
were detected in this study: 10 HR, 11 LR, 1 probably
carcinogenic and 4 possibly carcinogenic. Type 16 is the
most common type (41.9 %; 26/62), followed in order of
decreasing frequency, by HPV 18 (18/62; 29.03 %), HPV
31 (8/62; 12.9 %), HPV 58, 59, 6 (7/62; 11.3 %), HPV 45,
62, CP6108 (6/62;9.7 %), HPV 84 (5/62;8.1 %), HPV 33,
51, 66 (4/62;6.5 %), HPV 35, 52, 11, 61, 68 (3/62;4.8 %),
HPV 72, 81, 83 (2/62; 3.2 %) and HPV 40, 54, 67, 70, 73
(1/62; 1.6 %).
Discussion
This is the most recent study to estimate the prevalence
and type distribution of HPV in Egyptian women using
in vitro diagnostic (IVD) technique and by far it is the
largest HPV genotypes tested in a single study. In our
study, conducted at two large hospitals, 40.8 % (62/152)
of women attending routine gynecological examinations
were found to be HPV-positive. This was found to be
higher than the overall prevalence reported previously in
Egypt; 10.4 % [19], 10.3 % [4] and 15 % [15], in Northern
Africa (10.9 %) [4], and globally (11.4 %) [19]. This might
Table 1 Demographic characteristics, clinical and laboratory
findings of studied group
Characteristics (N = 150 (%)
Age (years) Mean ± SD 29.69 ± 4.88
Parity
Nullipara 25 (16.4 %)
Multipara 127 (83.6 %)
Residence
Urban 104 (68.4 %)
Rural 48 (31.6 %)
Occupation
Housewife 116 (76.3 %)
Worker 36 (23.7 %)
Smoking Status
No 136 (89.5 %)
Yes 16 (10.5 %)
Contraception method
None 62 (40.8 %)
IUCDsa 16 (10.5)
Injectables 10 (6.6 %)
COCPsb 36 (23.7 %)
POPsc 13 (8.6 %)
Condoms 15 (9.9 %)
Gynaecological findings
Normal 97(63.8 %)
Multiple genital warts 12 (7.9 %)
Intermenstrual bleeding 13 (8.5 %)
Post-coital bleeding 30 (19.7 %)
Pap smear & biopsy results
Normal 101 (67.1 %)
LSILd 35 (21.7 %)
HSILe 2 (2.0 %)
Invasive SCCf 14 (9.2 %)
HPV DNA
Negative 90 (59.2 %)
Positive 62 (40.8 %)
aIUCD intra uterine contraception device; bCOCPS Combined oral contraceptive
pills; cPOPS Progesterone only pills; dLSIL low grade squamous intra-epithelial
lesion; eHSIL high grade squamous intra-epithelial lesion; fSCC squamous
cell carcinoma
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Fig. 1 a Cytologic features of normal squamous epithelial cells with small pyknotic nuclei (Pap, x200). b Low-grade squamous intraepithelial
lesion with Human Papilloma Viral changes (Pap, x400). c High-grade squamous intraepithelial lesion. Nuclei are greatly enlarged, vary in size and
shape, and contain hyperchromatic, coarsely granular clumped chromatin (Pap, x400). d Invasive SCC showing nests of neoplastic squamous cells
invading through a chronically inflamed stroma (H&E, x200)
Fig. 2 a 2 % agarose gel electrophoresis showing 100 molecular weight marker (M), positive samples (HPV and β-globin genes DNA) in lanes 2,
3, 4, negative samples (β-globin genes DNA only) in lanes 6 & 7 and negative controls (lanes 1 & 5). b Linear Array HPV genotyping test strip
showing a colored band corresponding to HPV16 and β-globin genes
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be attributed to the fact that this study was cross-
sectional, and as HPV infections may be transient and
resolve on their own, the prevalence of HPV might
therefore change over time. Secondly, since the cervical
samples were collected only from women attending rou-
tine gynecological visits, there is a possibility of selection
bias. Nevertheless, a study in Egypt of HPV infection
among a high-risk group of female patients using PCR
in-situ hybridization of cervical biopsies revealed an ap-
proximately 70 % infection rate [15]. This high rate of
infection is attributed to the promiscuous sexual behav-
ior of the sampled women. Different rates of infection
have been recorded in different parts of the world.
Studies from different regions of the world such as
Greece have reported an overall HPV prevalence ranging
from 22.7 to 50.7 % [21, 22]. Kuhn et al. [23] in the
USA, Sellors et al. [24] in Canada, and Sun et al. [25] in
Taiwan reported HPV-positive rates of 18.1, 24, and
21 %, respectively. On the other hand, Varghese et al.
[26] reported 6.1 % among Indian women. This aug-
ments the findings of Becker et al. [27] that there are re-
gional and ethnic differences in HPV prevalence.
While HPV infection is considered a necessary precur-
sor to cervical cancer, it is not a sufficient cause. Other
determinants of the progression of HPV infection to cer-
vical cancer relate to the woman’s immune status. Those
Table 2 Relation and distribution of studied risk factors to HPV DNA status
DNA results (n = 152) p value
Negative (n = 90) Positive (n = 62)
Age (years) Mean ± S.D. 29.53 ± 4.61 29.93 ± 5.27 0.619
Age group (n, %)
21-25 years 19 (21.1 %) 14 (22.6 %)
26-30 years 35 (38.9 %) 19 (30.6 %) 0.741
31-35 years 25 (27.8 %) 19 (30.6 %)
35-40 years 11 (12.2 %) 10 (16.1 %)
Parity
Nullipara 15 (16.7 %) 10 (16.1 %) 0.930
Multipara 75 (83.3 %) 52 (83.9 %)
Residence
Urban 62 (68.9 %) 42 (67.7 %) 0.881
Rural 28 (31.1 %) 20 (32.3 %)
Occupation
Housewife 70 (77.8 %) 46 (74.2 %) 0.609
Worker 20 (22.2 %) 16 (25.8 %)
Smoking
No 81 (90.0 %) 55 (88.7 %) 0.799
Yes 9 (10.0 %) 7 (11.3 %)
Contraception
No 39 (43.3 %) 23 (37.1 %) 0.442
Yes 51 (56.7 %) 39 (62.9 %)
Gynecological findings
Normal (n = 97) 65 32
Multiple genital warts (n = 12) 0.0 (0 %) 12 (19.4 %) 0.000
Intermenstrual bleeding (13) 8.0 (8.9 %) 5.0 (8.1 %) 0.858
Post-coital bleeding (30) 17 (18.9 %) 13 (21.0 %) 0.752
Distribution of HPV DNA status according to cervical cytology and biopsy results
Normal (n = 101) 90 (100) 11 (17.7) 0.000a
LSIL (n = 35) 0.0 35 (56.5)
HSIL (n = 2) 0.0 2.0 (3.2)
Invasive SCC (n = 14) 0.0 14 (22.6)
aMC Monte Carlo Sig. (2-sided)
Youssef et al. Infectious Agents and Cancer  (2016) 11:6 Page 6 of 10
with an immune system compromised as a result of mal-
nutrition, pregnancy, or immunosuppressive chemother-
apy appear to be at increased risk of progression [28].
Additional cofactors, such a cigarette smoking, may be
required as a carcinogenic to advance HPV-infected cells
toward neoplastic progression [29]. Similarly, the study
of Abdel Aziz M.T. et al. [15], parity, smoking, history of
STD infection, as well as clinical vaginitis were among
the significant risk predictors distinguishing HPV-
negative and positive cases. On the other hand, smoking
and parity were studied among other predisposing fac-
tors in the current study, and were found to be insignifi-
cantly associated with HPV. This might be due to our
small sample size. The only finding that was statistically
significant was the presence of genital warts.
HPV infection is frequent among young women. How-
ever, most of the infections are cleared over a period of
6–12 months and only a small percentage develops a
persistent infection [5]. In the present study, there is a
higher HPV prevalence at younger ages (26–35 years of
age), but this was statistically insignificant. Several re-
searchers have found HPV infection rates to be higher in
younger age groups and it mainly depends on the age of
starting sexual activity [1, 24, 30]. Religion and cultural
upbringing of the Egyptian women may play a role in
protecting them from earlier infection [15].
In our study, HPV DNA positivity was 10.9 % (11/101)
in those with normal cytology. This agrees with the
study of Argyri E et al. [31], where HPV prevalence in
normal samples was 15.7 %. For Eastern Europe, HPV
prevalence in a meta-analysis of 4053 samples tested
with normal cytology was 21.4 % [32]. Similarly, the
study of Ozturk and coworkers [1] reported that HPV
DNA positivity was 2.1 % in women with normal cer-
vical cytology and 42.9 % in women with epithelial cell
abnormalities. They also reported that the presence of
HPV together with high rates of epithelial cell abnormal-
ities leading to cervical cancer supported the association
between HPV and malignancy. Also, in the study of
Abdel Aziz MT et al. [15], 28 % (7/106) of those who
were classified as having normal cytology recorded posi-
tive HPV DNA. The study of Panatto and coworkers
[33] showed that 18.2 % of the sexually active females
with normal cervical cytology were infected by at least
one HPV genotype. Ho and coworkers [29] reported that
women who are HPV DNA positive and lack cervical le-
sions are at greatly increased risk for developing SIL.
Hence the detection of HPV DNA in clinically and cyto-
logically normal women appears to have utility in
Table 4 HPV prevalence and type distribution
HPV prevalence/type N, %
HPV negative lesions 90/152 (59.2)
HPV positive lesions 62/152 (40.8)
Single Multiple Total
23/62 (37.1) 39/62 (62.9) 62 (100)
High risk HPV
16 5 (8.6) 21(33.9) 26 (41.9)
18 3 (4.8) 15(24.2) 18 (29.03)
31 0(0.0) 8(12.9) 8 (12.9)
33 0(0.0) 4(6.5) 4 (6.5)
35 0(0.0) 3(4.8) 3(4.8)
45 0(0.0) 6 (9.7) 6(9.7)
51 1(1.6) 3(4.8) 4(6.5)
52 0(0.0) 3(4.8) 3(4.8)
58 1(1.6) 6(9.7) 7(11.3)
59 0(0.0) 7(11.3) 7(11.3)
Low risk HPV
6 3(4.8) 4(6.5) 7(11.3)
11 2(3.2) 1(1.6) 3(4.8)
40 1(1.6) 0 (0.0) 1(1.6)
54 1(1.6) 0(0.0) 1(1.6)
61 0(0.0) 3(4.8) 3(4.8)
62 1(1.6) 5(8.6) 6(9.7)
72 0(0.0) 2(3.2) 2(3.2)
81 0(0.0) 2(3.2) 2(3.2)
83 0(0.0) 2(3.2) 2(3.2)
84 1(1.6) 4(6.5) 5(8.6)
CP6108 4(6.5) 2(3.2) 6(9.7)
Probably carcinogenic
68 0(0.0) 3(4.8) 3(4.8)
Possibly carcinogenic
66 0(0.0) 4(6.5) 4(6.5)
67 0(0.0) 1(1.6) 1(1.6)
70 0(0.0) 1(1.6) 1(1.6)
73 0(0.0) 1(1.6) 1(1.6)






HPV + ve cases





Normal 11 (17.7) 9(81.8) 2(18.2) 0 (0.0)
LSIL 35 (56.5) 2 (5.7) 5 (14.3) 28 (80)
HSIL 2 (3.2) 0(0.0) 0 (0.0) 2 (100)
Invasive SCC 14 (22.6) 2(14.3) 3 (21.4) 9 (64.3)
Total 62 (100) 13(20.9) 10 (16.1) 39 (62.9)
X2 = 33.683, pMC = 0.000*
aPercentage referred to the total number of HPV positivity
bPercentage referred to the number of HPV positive corresponding lesion
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identifying women at risk for progression to SIL. This
finding points to the drawbacks of using cytology alone
for detecting women at risk of cervical cancer. In con-
trast to cervical cytology, which is highly subjective,
HPV DNA testing is standardized and provides qualita-
tive and quantitative determination of the HPV DNA
present in a sample [23]. It has been proved that HPV
typing has an important role in the estimation of the risk
for high-grade cervical lesions [34].
In the current work, HPV DNA positivity was match-
ing with the study of Abdel Aziz MT et al. [15] showing
that the presence of SILs on cytological examination was
strongly associated with HPV DNA positivity using the
HC II assay. Ozturk and coworkers [1] reported that the
presence of HPV together with high rates of epithelial
cell abnormalities leading to cervical cancer supported
the association between HPV and malignancy. This
agrees with the study of Sellors and colleagues [24], who
reported that the presence of SILs on cytological exam-
ination was strongly associated with HPV DNA positiv-
ity using the HC II assay. Also, Carvahalo and coworkers
[35] reported that high-risk HPV types were present in
every case of SIL, i.e. 100 % correlation between high-
risk HPV types and cancer risk.
Among the 62 HPV positive samples, 26 HPV types
were detected, whether singly (23) or in combination
(38), using The LINEAR ARRAY Genotyping (LA) assay.
These data were in agreement with those of Giuliani L
et al. study [5], who typed 102 HPV positive samples by
sequencing and by the LINEAR ARRAY Genotyping
assay that showed mixed infections in 55 cases and sin-
gle infections in 46 cases. Gravit PE et al. [36] showed
that the PGMY09/11 primers used in the LINEAR
ARRAY presented an increased type-specific sensitivity,
particularly with samples infected with multiple types.
This explains the increased number of multiple infec-
tions observed by the LINEAR ARRAY.
The HR-HPV positivity in this study (16.1 %) was in
agreement with Panatto D et al. [33] study who recorded
a prevalence of HR- HPV genotypes of 10.1 %.
Moreover, HR HPV positivity increased as our stud-
ied lesions progressed to higher grade ones. Leinonen
M K et al. [37] found that none of the studied women
with a high grade cervical lesion had only low risk HPV
types. The same trend was observed in Argyri E et al.
[31] study where HR HPV positivity was related to
cytological status.
We demonstrated that LR HPV types were predomin-
ant in the cytologically normal women, while no LR
types were detected in HSIL. These data were consistent
with the work of Abdel Aziz MT et al. [15], where LR
HPV types were detected in cytologically normal sub-
jects, and SILs were exclusively associated with HR HPV
types, while no LR HPV types were found alone in SILs.
In the study of Argyri E et al. [31] in Greece, 12.9 % of
Greek women showed mixed infections, which is in har-
mony with our reported values (25, 6 %). In addition, the
same study reported that women with cervical lesions had
a higher rate of multiple infections compared to those
who had normal cytology, which agrees with our findings,
as all HPV types detected in cytologically normal women
were single infections, while the majority of cervical le-
sions reported multiple HPV infection. Multiple infections
might be a risk factor for development of cytological ab-
normalities. The majority of multi-HPV infected women
harbored at least one HR HPV type.
As previously reported, LINEAR ARRAY is known to
have a higher power in identifying mixed genotypes,
but the clinical implication of this higher power is not
well established [38–40]. One hypothesis could be that
the genotyping results are due to the nature of the
genotype detection used by the test: LA uses a strip
that is known to be more sensitive to detect a small
quantity of DNA [41].
Among the 26 HPV types detected in the 62 HPV
positive women in this study, HPV 16, 18 and 31 were
the most prevalent HR HPV types, and HPV 6, 62 and
CP6108 were the most prevalent LR HPV. These results
were consistent with data obtained from Shaltout et al.
[19], who reported predominance of HPV types 16, 31, 6
and 62, with the Halfon et al. [41] results who reported
HPV 16, 18 and 31 as prevalent genotypes using the
same LINEAR ARRAY methodology, with the global cir-
culating HPV types [32, 42] and with the worldwide esti-
mates that HPV-16 and 18 are responsible for nearly
70 % of cervical cancer cases [42]. But unlike our study,
Shaltout et al. [19] showed a relatively low (0.7 %) preva-
lence of HPV-18 in Egyptian women. Also, in contrast
to our results, other studies showed that HPV 11 was
the most frequent [43], while Argyri E et al. [31] found
that HPV 16, 42 and 51 were the most frequent.
Both the bivalent and quadrivalent vaccines provide
protection against HR HPV-16 and HPV-18 and have
been reported to provide cross-protection against non-
vaccine HR HPV-31, 33, 45, 52, or 58 [44, 45]. Since we
found additional HR HPV types circulating in the coun-
try, cross-protective properties of these vaccines might
protect Egyptian women from cervical cancers and pre-
cancer lesions.
Although this was a multicentre study, conducted in 2
large hospitals, it has some limitations. First, the sample
is representative of women presenting for smear testing.
However, as smear taking in Egypt is not done through
an organized screening system, our sample cannot be
considered representative of the Egyptian population.
These data may give us important information regarding
regional HPV prevalence but large epidemiological stud-
ies from different regions of our country are needed.
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Second, whereas more than 40 HPV types exist, only 26
types were detected in this study. But all HPV types
usually implicated in the origin of cervical cancer were
detected. Third, the small sample size affected the sig-
nificance of the results.
These data provide a complementary picture to studies
of HPV type distribution in Egyptian women with and
without cancer or precancerous lesions. Our results indi-
cated a higher prevalence of HPV infection (40.8 %).
They confirmed the importance of types 16 and 18 in
both single and multiple infections. They provide esti-
mates of the prevalence of other HR HPV types such as
31, and LR HPV types such as CP6108 in normal and
pathological lesions, indicating that other HPV types
must also be considered for further implementation of
appropriate immunization and monitoring policies.
Moreover, the considerable difference in frequency of
HPV types amongst previous studies evidences the need
to further investigations to improve information of geo-
graphical distribution of HPV types in Egypt over time
using standardized methodologies to HPV detection and
typing, to apply the appropriate diagnostic and therapeutic
measures, and to assess the impact of current vaccines
and to guide the introduction of new generations.
Conclusion
HPV testing for high risk viral types using the LINEAR
ARRAY assay can be used in apparently normal tissues.
This test may thus facilitate the detection of silent carriers
of HPV by a sensitive, non- invasive technique. It can also
be used as an adjunct to cytology to provide added sensi-
tivity. This will reduce further unnecessary investigations
and could contribute to cancer prevention. Despite that
LINEAR ARRAY is known to have a higher power in
identifying mixed genotypes, its clinical implication needs
further evaluation.
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